Medicus Pharma LTD Form 4 insider transactions

Medicus Pharma Ltd. Director Sara R. May acquired 25,000 stock options with an exercise price of $1.8, vesting quarterly over one year.

Medicus Pharma Ltd. Director Patrick J. Mahaffy was granted 25,000 stock options with an exercise price of $1.80, vesting quarterly over one year.

Medicus Pharma Ltd. Director Larry Kaiser was granted 25,000 stock options with an exercise price of $1.80, vesting quarterly over one year.

Medicus Pharma Ltd. director Barry Fishman was granted 25,000 stock options with an exercise price of $1.80, vesting quarterly over one year.

Medicus Pharma Ltd. Director Robert J. Ciaruffoli received a grant of 25,000 stock options with an exercise price of $1.80, vesting quarterly over one year.

Medicus Pharma's Chief Scientific Officer, Edward J. Brennan, was granted 50,000 stock options with an exercise price of $1.80, vesting quarterly over one year.

Medicus Pharma Ltd.'s President and CFO, Carolyn F. Bonner, was granted 75,000 stock options with an exercise price of $1.80 per share, vesting quarterly over one year.

Medicus Pharma Ltd. CEO Raza Bokhari was granted 125,000 stock options with an exercise price of $1.80, vesting quarterly over one year.

Medicus Pharma Ltd. Director William Ashton was granted 25,000 stock options with an exercise price of $1.8, vesting quarterly over one year.

Medicus Pharma's Chief Financial Officer, James P. Quinlan, exercised stock options to acquire 145,000 common shares, increasing his direct beneficial ownership to 274,147 shares.

Medicus Pharma Ltd. director and 10% owner Ajay Raju received a grant of 25,000 stock options with an exercise price of $3.08 for his service.

Medicus Pharma Ltd.'s Chief Financial Officer, James P. Quinlan, was granted 50,000 new stock options and saw 20,000 previously unvested options accelerate their vesting schedule.

Medicus Pharma's Chief Medical Officer, Faisal Mehmud, was granted 50,000 new stock options and had 100,000 existing options vest immediately, signaling increased executive alignment.

Medicus Pharma Ltd. Director Sara R. May reported the grant of 25,000 new stock options and the accelerated vesting of 15,000 previously granted options.

Medicus Pharma Ltd. Director Larry Kaiser reported the acquisition of new stock options and accelerated vesting of previously granted options, aligning his interests with the company's future performance.

Medicus Pharma Ltd. Director Barry Fishman reported the grant of 25,000 new stock options and the accelerated vesting of 15,000 previously granted options.

Medicus Pharma Ltd. Director and 10% Owner Robert J. Ciaruffoli reported the grant of 25,000 new stock options and the accelerated vesting of 15,000 previously granted options.

Medicus Pharma Ltd.'s Chief Scientific Officer, Edward J. Brennan, was granted 50,000 new stock options and had 20,000 previously unvested options accelerate their vesting schedule.

Medicus Pharma Ltd.'s President, Carolyn F. Bonner, received a grant of 50,000 new stock options and had 10,000 existing options accelerate vesting.

Medicus Pharma Ltd.'s CEO, Raza Bokhari, received a new grant of 250,000 stock options and saw 50,000 previously unvested options accelerate vesting.

Medicus Pharma Ltd. Director William Ashton was granted 25,000 new stock options and had 15,000 existing options undergo accelerated vesting, signaling continued alignment with company performance.

Velocity Fund Partners, LP sold 75,000 shares of Medicus Pharma Ltd. at a price of $7.7192 per share on May 20, 2025.